Mosley Wealth Management Has $822,000 Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Mosley Wealth Management reduced its position in Eli Lilly and Company (NYSE:LLY) by 10.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 908 shares of the company’s stock after selling 106 shares during the period. Eli Lilly and Company comprises 0.7% of Mosley Wealth Management’s holdings, making the stock its 27th largest position. Mosley Wealth Management’s holdings in Eli Lilly and Company were worth $822,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. AMJ Financial Wealth Management acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $201,000. Providence First Trust Co acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $274,000. Aveo Capital Partners LLC increased its stake in shares of Eli Lilly and Company by 8.2% during the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock worth $1,178,000 after purchasing an additional 153 shares during the period. Gryphon Financial Partners LLC lifted its holdings in Eli Lilly and Company by 19.4% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after purchasing an additional 377 shares during the last quarter. Finally, Heritage Investors Management Corp boosted its stake in Eli Lilly and Company by 8.5% in the 4th quarter. Heritage Investors Management Corp now owns 842 shares of the company’s stock valued at $491,000 after purchasing an additional 66 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.1 %

Shares of NYSE:LLY traded down $10.04 during mid-day trading on Friday, reaching $902.71. 3,439,999 shares of the company’s stock were exchanged, compared to its average volume of 3,063,074. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The firm has a market capitalization of $857.94 billion, a price-to-earnings ratio of 132.95, a PEG ratio of 2.91 and a beta of 0.41. The business’s fifty day moving average price is $895.97 and its 200-day moving average price is $827.49.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. On average, research analysts predict that Eli Lilly and Company will post 16.51 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Analysts Set New Price Targets

LLY has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their price objective for the stock from $725.00 to $1,025.00 in a research report on Monday, August 12th. Guggenheim lifted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Jefferies Financial Group increased their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a research report on Thursday, July 11th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $961.76.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares in the company, valued at approximately $91,109,731,514.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 737,410 shares of company stock worth $669,719,100 over the last three months. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.